Cytek Biosciences (NASDAQ:CTKB) just reported results for the second quarter of 2024.
- Cytek Biosciences reported earnings per share of -8 cents. This was below the analyst estimate for EPS of -3 cents.
- The company reported revenue of $46.62 million.
- This was 5.88% worse than the analyst estimate for revenue of $49.53 million.